Last reviewed · How we verify
NCT04078555
A Study to Evaluate ENERGI-F703 GEL in Venous Leg Ulcer
Phase 2 trial testing ENERGI-F703 GEL in Venous Leg Ulcer in 80 participants. Status unknown.
15 March 2025
Quick facts
| Lead sponsor | Energenesis Biomedical Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 26 July 2022 |
| Primary completion | 15 March 2025 |
| Estimated completion | 15 June 2025 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- ENERGI-F703 GEL — full drug profile →
- ENERGI-F703 GEL matched vehicle — full drug profile →
Conditions studied
- Venous Leg Ulcer — all drugs for Venous Leg Ulcer →
Sponsor
Energenesis Biomedical Co., Ltd. — full company profile →
Who can join
Adults 20 to 85, any sex, with Venous Leg Ulcer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, double-blind, placebo-controlled, phase II, multi-centered study to evaluate the efficacy and safety of ENERGI-F703 GEL in subjects who are ≥ 20 years old with venous leg ulcer (VLU). Subjects will be recruited from multiple sites in Taiwan. The treatment period will be 84 days with another 84-day follow-up period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04078555
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ENERGI-F703 GEL
Trials testing the same drug.
- NCT05930210 — A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer · Phase 3 · recruiting
Other recruiting trials for Venous Leg Ulcer
Currently open trials in the same condition.
- NCT07255937 — PMCF Study of Debridement Pad · NA · recruiting
- NCT07046767 — CAMP RWE Trial: Amnion Grafts for Healing Hard-to-Heal Ulcers in RW Populations · NA · recruiting
- NCT07211243 — Suprasorb®X+PHMB Pro vs Suprasorb®X+PHMB in Treatment of Infected Venous Leg Ulcers · NA · recruiting
- NCT07061613 — Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Venous Leg Ulcers · NA · recruiting
- NCT06544564 — Human Amniotic Membrane On Venous Leg Ulcers In an Elderly Population · NA · recruiting
Other Energenesis Biomedical Co., Ltd. trials
Trials by the same sponsor.
- NCT05930210 — A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer · Phase 3 · recruiting
- NCT03351322 — ENERGI-F701 for Female Hair Loss Treatment · Phase 2 · completed
- NCT02672436 — ENERGI-F703 for Diabetic Foot Ulcers Phase II Study · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04078555 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Energenesis Biomedical Co., Ltd.
- Last refreshed: 20 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04078555.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing